Medicare To Reimburse Guardant Health's Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue
1. CMS approved ADLT status for Guardant Health's Shield blood test for CRC. 2. FDA approved Shield as the first blood test for primary CRC screening. 3. Shield test will be reimbursed at $1,495 starting April 1 for Medicare patients. 4. Analysts project an additional $10 million revenue due to reimbursement increase. 5. GH stock rose 14.5% to $41.04 following the announcement.